Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Matrix-producing carcinoma of the breast: an aggressive subtype of metaplastic carcinoma.

Downs-Kelly E, Nayeemuddin KM, Albarracin C, Wu Y, Hunt KK, Gilcrease MZ.

Am J Surg Pathol. 2009 Apr;33(4):534-41. doi: 10.1097/PAS.0b013e31818ab26e.

PMID:
19047898
2.

[Matrix-producing metaplastic carcinoma: a clinicopathologic and prognostic analysis of 16 cases with review of literature].

Zhang Z, Bu H, Huang H, Zhang J, Lang Z, Zhao T, Wang J, Liao D, Wei B.

Zhonghua Bing Li Xue Za Zhi. 2014 Aug;43(8):528-32. Chinese.

PMID:
25346122
3.

Unique clinicopathological features of metaplastic breast carcinoma compared with invasive ductal carcinoma and poor prognostic indicators.

Song Y, Liu X, Zhang G, Song H, Ren Y, He X, Wang Y, Zhang J, Zhang Y, Sun S, Liang X, Sun Q, Pang D.

World J Surg Oncol. 2013 Jun 6;11:129. doi: 10.1186/1477-7819-11-129.

4.

Matrix-producing carcinoma of the breast in the Chinese population: a clinicopathological study of 13 cases.

Shui R, Bi R, Cheng Y, Lu H, Wang J, Yang W.

Pathol Int. 2011 Jul;61(7):415-22. doi: 10.1111/j.1440-1827.2011.02676.x. Epub 2011 May 18.

PMID:
21707845
5.

Metaplastic breast carcinoma with extensive osseous differentiation: a report of two cases and review of the literature.

Lang R, Fan Y, Fu X, Fu L.

Tumori. 2011 Jul-Aug;97(4):e1-5. doi: 10.1700/950.10411. Review.

6.

Pleomorphic ductal carcinoma of the breast: predictors of decreased overall survival.

Nguyen CV, Falcón-Escobedo R, Hunt KK, Nayeemuddin KM, Lester TR, Harrell RK, Bassett RL Jr, Gilcrease MZ.

Am J Surg Pathol. 2010 Apr;34(4):486-93. doi: 10.1097/PAS.0b013e3181ce97bf.

PMID:
20154588
7.

Outcomes of locally advanced breast cancer patients with ≥ 10 positive axillary lymph nodes.

Koca E, Kuzan TY, Dizdar O, Babacan T, Sahin I, Ararat E, Altundag K.

Med Oncol. 2013;30(3):615. doi: 10.1007/s12032-013-0615-7. Epub 2013 Jun 1.

PMID:
23729267
8.

Matrix-producing mammary carcinoma: a rare breast tumor.

Mardi K, Sharma J.

Indian J Pathol Microbiol. 2008 Apr-Jun;51(2):263-4. Review.

9.

Invasive ductal carcinoma of the breast with a large central acellular zone associated with matrix-producing carcinoma.

Hama Y, Tsuda H, Sato K, Hiraide H, Mochizuki H, Kusano S.

Tumori. 2004 Sep-Oct;90(5):498-500.

PMID:
15656336
10.

Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade.

Makretsov NA, Hayes M, Carter BA, Dabiri S, Gilks CB, Huntsman DG.

Mod Pathol. 2007 Jan;20(1):84-9. Epub 2006 Nov 24.

11.

Ductal carcinoma in situ (intraductal carcinoma) of the breast treated with breast-conserving surgery and definitive irradiation. Correlation of pathologic parameters with outcome of treatment.

Solin LJ, Yeh IT, Kurtz J, Fourquet A, Recht A, Kuske R, McCormick B, Cross MA, Schultz DJ, Amalric R, et al.

Cancer. 1993 Apr 15;71(8):2532-42.

12.

Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival.

Dieterich M, Hartwig F, Stubert J, Klöcking S, Kundt G, Stengel B, Reimer T, Gerber B.

Breast. 2014 Aug;23(4):346-51. doi: 10.1016/j.breast.2014.01.015. Epub 2014 Feb 18.

PMID:
24559611
13.

Survival benefit of post-mastectomy radiotherapy in breast carcinoma patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasis.

Duraker N, Demir D, Bati B, Yilmaz BD, Bati Y, Çaynak ZC, Sobutay E.

Jpn J Clin Oncol. 2012 Jul;42(7):601-8. doi: 10.1093/jjco/hys052. Epub 2012 Apr 17.

PMID:
22511807
14.

Local recurrences and distant metastases after breast-conserving surgery and radiation therapy for early breast cancer.

Touboul E, Buffat L, Belkacémi Y, Lefranc JP, Uzan S, Lhuillier P, Faivre C, Huart J, Lotz JP, Antoine M, Pène F, Blondon J, Izrael V, Laugier A, Schlienger M, Housset M.

Int J Radiat Oncol Biol Phys. 1999 Jan 1;43(1):25-38.

PMID:
9989511
15.

Age and associated fibrocystic changes are prognostically significant in patients with small node-negative (T1a,bN0) invasive breast cancer.

Durak MG, Gonzalez-Angulo AM, Hanrahan EO, Broglio KR, Valero V, Hortobagyi GN, Hunt KK, Sahin AA.

Breast J. 2011 Sep-Oct;17(5):462-9. doi: 10.1111/j.1524-4741.2011.01116.x. Epub 2011 Jul 5.

PMID:
21726347
16.

Metaplastic carcinoma of the breast with osteocartilaginous heterologous elements.

Chhieng C, Cranor M, Lesser ME, Rosen PP.

Am J Surg Pathol. 1998 Feb;22(2):188-94.

PMID:
9500219
17.

Therapeutic options and results for the management of minimally invasive carcinoma of the breast: influence of axillary dissection for treatment of T1a and T1b lesions.

White RE, Vezeridis MP, Konstadoulakis M, Cole BF, Wanebo HJ, Bland KI.

J Am Coll Surg. 1996 Dec;183(6):575-82.

PMID:
8957459
18.

Centrally necrotizing carcinomas of the breast: a distinct histologic subtype with aggressive clinical behavior.

Jimenez RE, Wallis T, Visscher DW.

Am J Surg Pathol. 2001 Mar;25(3):331-7.

PMID:
11224603
19.

Histological factors for accurately predicting first locoregional recurrence of invasive ductal carcinoma of the breast.

Hasebe T, Iwasaki M, Hojo T, Shibata T, Kinoshita T, Tsuda H.

Cancer Sci. 2013 Sep;104(9):1252-61. doi: 10.1111/cas.12217. Epub 2013 Jul 25.

20.

HER-2 positive breast cancer is associated with an increased risk of positive cavity margins after initial lumpectomy.

Jia H, Jia W, Yang Y, Li S, Feng H, Liu J, Rao N, Jin L, Wu J, Gu R, Zhu L, Chen K, Deng H, Zeng Y, Liu Q, Song E, Su F.

World J Surg Oncol. 2014 Sep 20;12:289. doi: 10.1186/1477-7819-12-289.

Supplemental Content

Support Center